Autoimmune Polyendocrinopathy Syndrome Type Ⅱ：a Case Report and Literature Review
1.Department of Endocrinology，Affiliated Hospital of Integrated Traditional Chinese and Western Medicine，Nanjing University of Chinese Medicine，Nanjing 210028，China
2.Key Research Laboratory of Gall Disease Syndrome and Treatment，Jiangsu Province Academy of Traditional Chinese Medicine，Nanjing 210028，China
3.Xinyi Central Hospital，Xinyi 221400，China
*Corresponding author：CAO Wen，Associate chief physician；E-mail：caow1900@126.com
XIANG Pingping,SU Xiaohui,DI Hongjie, et al. Autoimmune Polyendocrinopathy Syndrome Type Ⅱ：a Case Report and Literature Review [J]. Chinese General Practice, 2019, 22(35): 4401-4405. DOI: 10.12114/j.issn.1007-9572.2019.00.294.
相萍萍,苏晓辉,狄红杰等. 自身免疫性多内分泌腺病综合征Ⅱ型一例报道并文献复习[J]. 中国全科医学, 2019, 22(35): 4401-4405. DOI: 10.12114/j.issn.1007-9572.2019.00.294.
［1］HUSEBYE E S，ANDERSON M S，K?MPE O.Autoimmune polyendocrine syndromes［J］．N Engl J Med，2018，378（12）：1132-1141．DOI：10.1056/NEJMra1713301.
［2］NAGAMINE K，PETERSON P，SCOTT H S，et al．Positional cloning of the APECED gene［J］．Nat Genet，1997，17（4）：393-398．DOI：10.1038/ng1297-393.
［3］EISENBARTH G，WILSON P，WARD F，et al．HLA type and occurrence of disease in familial polyglandular failure［J］．N Engl J Med，1978，298（2）：92-94．DOI：10.1056/NEJM197801122980209.
［4］BOTTINI N，MUSUMECI L，ALONSO A，et al．A functional variant of lymphoid tyrosine phosphatase is associated with type Ⅰ diabetes［J］．Nat Genet，2004，36（4）：337-338．DOI：10.1038/ng1323.
［5］UEDA H，HOWSON J M，ESPOSITO L，et al．Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease［J］．Nature，2003，423（6939）：506-511．DOI：10.1038/nature01621.
［6］MICHELS A W，EISENBARTH G S.Autoimmune polyendocrine syndrome type 1 （APS-1） as a model for understanding autoimmune polyendocrine syndrome type 2 （APS-2）［J］．J Intern Med，2009，265（5）：530-540．DOI：10.1111/j.1365-2796.2009.02091.x.
［7］POPLER J，ALIMOHAMMADI M，K?MPE O，et al．Autoimmune polyendocrine syndrome type 1：utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab［J］．Pediatr Pulmonol，2012，47（1）：84-87．DOI：10.1002/ppul.21520.
［8］GUO C J，LEUNG P S C，ZHANG W C，et al．The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome （APS-1）［J］．Autoimmun Rev，2018，17（1）：78-85．DOI：10.1016/j.autrev.2017.11.012.
［9］BARTALENA L，BALDESCHI L，BOBORIDIS K，et al．The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of Graves' orbitopathy［J］．Eur Thyroid J，2016，5（1）：9-26．DOI：10.1159/000443828.
［10］ABULAYHA A，BREDAN A，EL ENSHASY H，et al．Rituximab：modes of action，remaining dispute and future perspective［J］．Future Oncol，2014，10（15）：2481-2492．DOI：10.2217/fon.14.146.
［11］SALVI M，VANNUCCHI G，CURRò N，et al．Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy：a randomized controlled study［J］．J Clin Endocrinol Metab，2015，100（2）：422-431．DOI：10.1210/jc.2014-3014.
［12］RUDNICKI M.Rituximab for treatment of membranoproliferative glomerulonephritis and C3 glomerulopathies［J］．Biomed Res Int，2017，2017：2180508．DOI：10.1155/2017/2180508.
［13］ROBERTS A，JAMES J，DHATARIYA K，et al．Management of hyperglycaemia and steroid （glucocorticoid） therapy：a guideline from the Joint British Diabetes Societies （JBDS） for Inpatient Care group［J］．Diabet Med，2018，35（8）：1011-1017．DOI：10.1111/dme.13675.
［14］ROSS D S，BURCH H B，COOPER D S，et al．2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis［J］．Thyroid，2016，26（10）：1343-1421．DOI：10.1089/thy.2016.0229.
